TABLE 2

Resource Use Characteristics

Overall (N = 32 354)2009–2013 (n = 14 785)2014–2018 (n = 17 569)P
Laboratory, n (%)
 CBC17 786 (55)8284 (56)9502 (54.1)<.001
 Electrolyte test27 639 (85.4)13 032 (88.1)14 607 (83.1)<.001
 Urine culture8257 (25.5)4175 (28.2)4082 (23.2)<.001
 Urinalysis14 461 (44.7)6884 (46.6)7577 (43.1)<.001
 Rotavirus5349 (16.5)3748 (25.4)1601 (9.1)<.001
 Stool studies10 593 (32.7)6258 (42.3)4335 (24.7)<.001
Pharmacy, n (%)
 Antibiotics4676 (14.5)2400 (16.2)2276 (13)<.001
 Probiotics6837 (21.1)3208 (21.7)3629 (20.7).022
 IV fluids27 217 (84.1)12 440 (84.1)14 777 (84.1).940
 Antiemeticsa18 838 (58.2)8044 (54.4)10 794 (61.4)<.001
Imaging, n (%)
 CT2257 (7)1147 (7.8)1110 (6.3)<.001
 Radiograph12 080 (37.3)5815 (39.3)6265 (35.7)<.001
 Ultrasound7573 (23.4)2751 (18.6)4822 (27.4)<.001
Clinical course
 Median LOS (IQR),h35 (22–49)35 (21–49)34 (22–48).575
 14-d revisit, n (%)2483 (7.7)1054 (7.1)1429 (8.1).001
  • CBC, complete blood cell count.

  • a Ondansetron, chlorpromazine, and prochlorperazine.